#United States #Charleston #Afaxys #Christian Bloomgren #Ronda Dean

Afaxys Announces Leadership Changes

On October 13, 2025, Afaxys, Inc. revealed significant changes in its leadership team as they prepare for a new chapter in their mission. Ronda Dean, co-founder and CEO, will be retiring effective January 2, 2026, after 17 years of service. She has been a pivotal figure in establishing Afaxys as a socially responsible healthcare company focused on serving public health professionals and their patients. In her place, Christian Bloomgren, the current President and Chief Commercial Officer, will take on the roles of President and CEO.

Ronda Dean's journey at Afaxys has been marked by dedication to reproductive justice and gender equity. “I am incredibly grateful for the support and commitment of my colleagues and partners over the years,” she expressed in her farewell announcement. Under her leadership, Afaxys has successfully aided millions of patients, a legacy she believes will continue with Bloomgren at the helm. Dean will transition to an advisory role to support Bloomgren and the company’s goals.

Christian Bloomgren brings more than 25 years of experience in the pharma and healthcare industry, particularly in women's health. His tenure at Afaxys has involved leading marketing and sales initiatives, aiming to propel the company’s growth and mission forward. As he embarks on this new role, Bloomgren reiterated his commitment to continuing the critical work established by Dean. He stated, “My priority is to remain true to our mission while positioning Afaxys for even greater growth and impact.”

The board of Afaxys also expressed gratitude for Dean's transformative leadership. Sarah Stoesz, Chair of the Board, commended Dean for her contributions and emphasized the importance of selecting a successor who understands the mission deeply. Stoesz expressed confidence in Bloomgren's ability to lead the company into its next growth phase.

Afaxys operates as a Public Benefit Corporation, striving to ensure healthcare professionals have stable pricing and reliable access to necessary products and services, aligning private industry with public health needs. The company’s operations fall under three subsidiaries: Afaxys Pharma, Afaxys Drug Development, and Afaxys Group Services, each contributing to a diverse healthcare portfolio focused on women's health needs.

As Afaxys continues its journey in the healthcare sector, the leadership transition marks a significant moment not just for the company but for the broader public health landscape it serves. Both Dean and Bloomgren have expressed confidence that their combined efforts and the organization's mission will persist in making a positive impact for years to come.

For further updates on Afaxys and its ongoing mission, visit Afaxys' official website.